No previous suggestions found.

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

Ionis Pharmaceuticals

#2497

Rank

$5.98B

Marketcap

US United States

Country

Ionis Pharmaceuticals
Leadership team

Dr. Brett P. Monia Ph.D. (Founder, CEO & Director)

Ms. Elizabeth L. Hougen (Exec. VP of Fin. & CFO)

Ms. Onaiza Cadoret-Manier (Exec. VP, Chief Global Product Strategy & Operations Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
500 - 1000
Headquarters
Carlsbad, California, United States
Established
1989
Company Registration
SEC CIK number: 0000874015
Net Income
5M - 20M
Revenue
500M - 1B
Traded as
IONS
Social Media
URL
https://www.ionispharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
History

The company was founded in 1989 as Isis Pharmaceuticals by Stanley T. Crooke, a former head of research of GlaxoSmithKline, with a goal to commercialize antisense therapy.In 1992, the company received its first approval by the Food and Drug Administration for an investigational new drug application in 1992 for a genital warts drug candidate. The FDA approval marked the first time for the company to conduct any antisense therapy and to be tested in humans.In 1995, the genital warts drug failed in clinical trials and Isis terminated development. By that time, Gilead Sciences and Genta had left the antisense therapy field, leaving only Isis, Hybridon, and Lynx Therapeutics working in the field. Gilead sold its patents, developed around antisense, to Isis.In December 2015, Isis changed its name to Ionis, driven in part by the negative image of "Isis" generated by the terrorist group, Islamic State of Iraq and the Levant, commonly known as ISIL or ISIS.In 2017, the company completed the corporate spin-off of its rare lipid disorder subsidiary, Akcea Therapeutics.

Mission
Our mission is to use the science of antisense to target and treat—to the greatest possible degree—the underlying cause of disease and improve patients’ lives
Vision
Our vision is to build a world-leading biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines.
Key Team

Mr. Patrick R. O'Neil Esq. (Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.)

Dr. Stanley T. Crooke (Scientific Advisor)

Ms. B. Lynne Parshall Esq., J.D. (Sr. Strategic Advisor & Director)

Dr. Eric E. Swayze Ph.D. (Exec. VP of Research)

Mr. Joel Edwards (VP of Corp. Operations)

Mr. Darren Gonzales (Chief Accounting Officer & Sr. VP)

Dr. C. Frank Bennett (Exec. VP & Chief Scientific Officer)

Recognition and Awards
Ionis Pharmaceuticals has been the recipient of numerous awards and accolades, including the Global Genes RARE Impact award in 2016, the Prix Galien USA Award for Best Biotechnology Product in 2017, and the 2018 BioTech Breakthrough Award for Antisense Research & Development
References

https://en.wikipedia.org/wiki/Ionis_Pharmaceuticals

https://in.investing.com/equities/isis-pharma

https://finance.yahoo.com/quote/IONS/profile?p=IONS

https://www.comparably.com/companies/ionis-pharmaceuticals/mission

https://www.crunchbase.com/organization/ionis-pharmaceuticals

https://sec.report/CIK/0000874015

https://companiesmarketcap.com/

https://www.ionispharma.com

Ionis Pharmaceuticals
Leadership team

Dr. Brett P. Monia Ph.D. (Founder, CEO & Director)

Ms. Elizabeth L. Hougen (Exec. VP of Fin. & CFO)

Ms. Onaiza Cadoret-Manier (Exec. VP, Chief Global Product Strategy & Operations Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
500 - 1000
Headquarters
Carlsbad, California, United States
Established
1989
Company Registration
SEC CIK number: 0000874015
Net Income
5M - 20M
Revenue
500M - 1B
Traded as
IONS
Social Media
URL
https://www.ionispharma.com
About

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

contacts

businessabc@ztudium.com

Follow Us
Produced by
In collaboration with
Logo

Copyright 2024 © Businessabc powered by ztudium

Privacy Policy